Aclaris Therapeutics Stock
Aclaris Therapeutics, Inc.
Company data
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- CEO
- Neal S. Walker
- Employees
- 71
- Market cap
- $483 M
- IPO
- 06/10/2015
Aclaris Therapeutics, Inc., a biopharmaceutical firm operating in the United States, is currently in the clinical development phase, focused on creating novel therapeutic agents for various immune-inflammatory conditions. The company's operations are divided into two primary divisions: the Therapeutics segment,…
Aclaris Therapeutics stock: price history
1D
-6.0%
1W
-14.4%
1M
-38.3%
6M
-22.8%
YTD
+9.0%
1Y
+60.0%
2Y
+182.8%
5Y
-80.5%
10Y
-85.5%
Next earnings date
Next earnings date
05/11/2026 (in 19 days)
Volatility around earnings
~33% weaker price swings than usual
Aclaris Therapeutics stock scores
- Valuation
Visible after free registration
- Trend
Visible after free registration
- Quality
Visible after free registration
- Dividend
Visible after free registration
- Growth
Visible after free registration
- Insider
Visible after free registration
- Earnings
Visible after free registration
- Revisions
Visible after free registration
- Sentiment
Visible after free registration
- Short Pressure
Visible after free registration
Register for free
Unlock all 11 scores
- 5 credits free on registration
- Access to virtual portfolios and watchlist
- No credit card, no payment details needed
- No subscription, no minimum term
- Our own servers in Germany, no US cloud
Deterministically calculated from financial metrics, not investment advice. Updated nightly, last on 17/10/2026.
Business model & megatrends
Average business model without a clear megatrend link or with mixed signals.
1 more assignment (Enabler/Second row) Pro-only.
Aclaris Therapeutics is a clinical-stage biopharmaceutical company specializing in the development of novel therapeutics for various inflammatory and immunological diseases. The business model comprises two segments: a therapeutic agents segment for treating diseases such as rheumatoid arthritis and atopic dermatitis, and a contract research segment. Current revenue is primarily generated through licensing agreements, services, and research projects.
- Revenue model
- Transactional
- Recurring revenue
- None
- Pricing power
- Weak
- Moat
- Narrow
- Moat type
- Efficient scale
- Capital intensity
- High
- Customer concentration
- Unknown
Ask the agents about Aclaris Therapeutics
Analyst assessment of Aclaris Therapeutics
PRICE TARGET LOW
US$10.00
CONSENSUS
US$10.75
MEDIAN
US$10.50
PRICE TARGET HIGH
US$12.00
0
STRONG BUY
13
BUY
3
HOLD
0
SELL
0
STRONG SELL
16
TOTAL · Buy
As of: 05/05/2026
Aclaris Therapeutics stock metrics
P/E
-5.66
P/B
3.76
EV/EBITDA
-6.16
RETURN ON EQUITY
-17.3%
NET MARGIN
-1,320.1%
DEBT/EQUITY
0
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
75.4%
FLOAT SHARES
111,055,463
AVG. DAILY VOLUME (30D)
3,724,368
Insider transactions (SEC)
Kolbeck Roland Wilhelm
Kolbeck Roland Wilhelm
GOWEN MAXINE
Mehra Anand
Molineaux Christopher P.
Attention
1 mention today in US forums, about the same as yesterdayPrice since yesterday: -6.0%
Forums (Reddit)
Institutional holders
Comparable stocks
Frequently asked questions about Aclaris Therapeutics stock
What does Aclaris Therapeutics do?
Aclaris Therapeutics, Inc. is a company in the Healthcare sector, Biotechnology industry, headquartered in United States.
The CEO is Neal S. Walker, the company employs around 71 people.
The IPO was on 06/10/2015; the stock trades on NASDAQ under the ticker ACRS.
What do analysts say about Aclaris Therapeutics stock?
16 analysts rate the stock, the consensus is Buy (as of 05/05/2026).
The average price target is US$10.75, ranging from US$10.00 to US$12.00, with a median of US$10.50.
This is an external assessment, not a statement by Market Jury.
When does Aclaris Therapeutics report next?
The next earnings date is 05/11/2026.
Around past earnings, price swings were roughly -33% stronger than usual.
Does Aclaris Therapeutics pay a dividend?
No, Aclaris Therapeutics currently does not pay a dividend.
Which stocks are comparable to Aclaris Therapeutics?
Comparable stocks include Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals, Revolution Medicines, Incyte, Exelixis, Neurocrine Biosciences and Summit Therapeutics.
How can I get Aclaris Therapeutics stock analyzed?
Clicking "Analyze stock" lets five strategies assess Aclaris Therapeutics against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.